Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1626
This examiner grants 70% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18009310 | 5-OXOPYRROLIDINE-3-CARBOXAMIDES AS NAV1.8 INHIBITORS | Final Rejection | MERCK SHARP & DOHME LLC |
| 18450014 | PHOSPHANE GOLD(I)-N-HETEROCYCLIC CARBENE COMPLEXES FOR TREATING CANCER | Non-Final OA | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS |
| 18548530 | PROCESS FOR PREPARING ALKYL-4-OXOTETRAHYDROFURAN-2-CARBOXYLATE | Non-Final OA | Bayer Aktiengesellschaft |
| 18253273 | BRAIN-MIGRATING TUMOR THERAPEUTIC AGENT CONTAINING FUSED PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | Final Rejection | TAIHO PHARMACEUTICAL CO., LTD. |
| 18275847 | FLAVONE DEAZA SPERMIDINE ANALOGUES AND THEIR USE TREATING CANCER | Non-Final OA | FLORATEK PHARMA S.A. |
| 18375063 | KINASE MODULATORS AND METHODS OF USE THEREOF | Non-Final OA | NEURON23, INC. |
| 18218610 | PROCESS FOR THE PREPARATION OF ISAVUCONAZONIUM SULFATE | Non-Final OA | RK Pharma Inc. |
| 18254450 | DEUTERATED 2-ARYLHETEROCYCLE-3-OXO-2,3- DIHYDROPYRIDAZINE-4-CARBOXAMIDE INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Final Rejection | SUZHOU ZELGEN BIOPHARMACEUTICALS CO., LTD. |
| 17491676 | 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | Final Rejection | Rugen Holdings (Cayman) Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy